← Leaderboards
Scott R Penzak
Clinical Center
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Clinical Center
Same institution · by research overlap
- Mark Thomas Gladwin$38,765,597
- Scott Penzak$0
- Nadja Rehak$0
Others in their field
Top investigators on “Protease Inhibitor”
- Constance Ann Benson · University Of California, San Diego$150,461,206
- Robert Turner Schooley · University Of Colorado Denver$48,400,257
- John Damon Chodera · Sloan-Kettering Inst Can Research$40,777,114
- Daniel R Kuritzkes · Brigham And Women'S Hospital$26,572,064
- David Heimbrook · Leidos Biomedical Research, Inc.$26,054,235
- Celia A. Schiffer · Univ Of Massachusetts Med Sch Worcester$24,364,826
Research focus
Protease InhibitorHuman SubjectRitonavirPharmacokineticsClinical ResearchDrug KineticsDoseGenotypePlasmaPharmaceutical PreparationsDailyMidazolamDrug InteractionsHiv InfectionsCytochrome P450InvestigationPurposeOralP GlycoproteinPhenotypeCyp3a4 GeneBaseHiv Protease InhibitorsToxic Effect
Grant awards (27)
The Influence of Herbal Supplements on Lopinavir/Ritonavir Pharmacokinetics$30,448
Z01 · FY2008 · CL · contact PI
Prednisolone Pharmacokinetics in the Presence and Absence of Ritonavir$24,358
Z01 · FY2008 · CL · contact PI
Association of CYP2B6 Genotype and Efavirenz Metabolism$12,179
Z01 · FY2008 · CL · contact PI
Influence Of Mdr-1 Genotype On Indinavir And Saquinavir Pharmacokinetics$6,090
Z01 · FY2008 · CL · contact PI
The Influence of Herbal Supplements on Lopinavir/Ritonavir Pharmacokinetics$31,000
Z01 · FY2007 · CL · contact PI
Prednisolone Pharmacokinetics in the Presence and Absence of Ritonavir$24,800
Z01 · FY2007 · CL · contact PI
Association of CYP2B6 Genotype and Efavirenz Metabolism$12,400
Z01 · FY2007 · CL · contact PI
Influence Of Mdr-1 Genotype On Indinavir And Saquinavir Pharmacokinetics$6,200
Z01 · FY2007 · CL · contact PI
Prednisolone Pharmacokinetics in the Presence and Absenc$0
Z01 · FY2006 · CL · contact PI
Influence Of Mdr-1 Genotype On Indinavir And Saquinavir$0
Z01 · FY2006 · CL · contact PI
Global initiative to characterize antiretroviral pharmac$0
Z01 · FY2006 · CL · contact PI
Association of CYP2B6 Genotype and Efavirenz Metabolism$0
Z01 · FY2006 · CL · contact PI
The Influence of Herbal Supplements on Lopinavir/Ritonav$0
Z01 · FY2006 · CL · contact PI
Association of CYP2B6 Genotype and Efavirenz Metabolism$0
Z01 · FY2005 · CL
Global initiative to characterize antiretroviral pharmac$0
Z01 · FY2005 · CL
Influence Of Mdr-1 Genotype On Indinavir And Saquinavir$0
Z01 · FY2005 · CL
Prednisolone Pharmacokinetics and Ritonavir$0
Z01 · FY2005 · CL
The Influence of Herbal Supplements on Lopinavir/Ritonav$0
Z01 · FY2005 · CL
Prednisolone Pharmacokinetics in Presence of Ritonavir$0
Z01 · FY2004 · CL
Influence Of Mdr-1 Genotype On Indinavir And Saquinavir$0
Z01 · FY2004 · CL
Global study: Antiretroviral pharmacokinetics$0
Z01 · FY2004 · CL
Global initiative to characterize antiretroviral pharmac$0
Z01 · FY2003 · CL
Prednisolone Pharmacokinetics With and Without Ritonavir$0
Z01 · FY2003 · CL
Influence Of Mdr-1 Genotype On Indinavir And Saquinavir$0
Z01 · FY2003 · CL
Influence Of Mdr-1 Genotype On Indinavir And Saquinavir$0
Z01 · FY2002 · CL
ILow-dose Ritonavir On The Pharmacokinetics of Digoxin$0
Z01 · FY2002 · CL
Global initiative to characterize antiretroviral pharmac$0
Z01 · FY2002 · CL